Human Cripto-1 and Cripto-3 Protein Expression in Normal and Malignant Settings That Conflicts with Established...

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cripto-1 (CR1) is an embryonic protein vital for implantation, re-expressed in adults during repair, inflammation, and cancer.
• CR1 and its pseudogene product Cripto-3 (CR3) are highly homologous, making discrimination difficult with existing antibodies.

Purpose of the Study:

• To develop specific monoclonal antibodies (MoAbs) capable of differentiating between human CR1 and CR3 proteins.
• To investigate the expression and function of CR3 in human cancer and its interaction with other signaling molecules.

Main Methods:

• Generation of high-affinity mouse monoclonal antibodies (MoAbs) with specific binding to human CR1/CR3.
• Validation of antibody specificity and lack of cross-reactivity.
• Detection of CR3 protein in tumor tissues, cell lysates, and patient sera.
• Analysis of CR1 and CR3 competition for binding to Nodal, GRP78, and Alk4.

Main Results:

• Developed discriminatory MoAbs confirming CR3 as a translated protein in human tumors, cancer cell lysates, and patient sera.
• Demonstrated that CR1 and CR3 compete for binding to Nodal, GRP78, and Alk4.
• Challenged existing conventions regarding CR1/CR3 protein expression and clarified their roles.

Conclusions:

• CR3 is a bona fide protein involved in human carcinogenesis and cell signaling pathways.
• The new MoAbs are valuable reagents for resolving CR1/CR3 expression ambiguities.
• Findings have potential clinical relevance for cancer patient prognosis and disease severity assessment.